Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pharmather Hldgs Ltd (OP:PHRRF)

0.0740 UNCHANGED

Streaming Delayed Price Updated: 3:14 PM EST, Jan 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	0.0740
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0740
Today's Range	0.0740 - 0.0740
52wk Range	0.0656 - 0.5500
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

PharmaTher CEO Publishes Letter to Shareholders

January 02, 2026

Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that...

Via Newsfile

PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise

December 02, 2025

Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a...

Via Newsfile

Performance

YTD	N/A	N/A
1 Month	-14.9%	-14.9%
3 Month	-45.3%	-45.3%
6 Month	-77.0%	-77.0%
1 Year	-53.7%	-53.7%

More News

PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program

November 17, 2025

Via Newsfile

PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale

October 17, 2025

Via Newsfile

PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease

October 16, 2025

Via Newsfile

PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings

October 15, 2025

Via Newsfile

PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease

October 08, 2025

Via Newsfile

PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy

October 02, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments

October 01, 2025

Via Newsfile

PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments

October 01, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative

August 27, 2025

Via Newsfile

PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)

August 26, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine (KETARx(TM))

August 14, 2025

Via Newsfile

PharmaTher Founder and CEO Issues Letter to Shareholders following the FDA Approval of Ketamine (KETARx™)

August 14, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Announces FDA Approval of Ketamine (KETARx(TM))

August 11, 2025

Via Newsfile

PharmaTher Announces FDA Approval of Ketamine (KETARx™)

August 11, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Announces Path to Ketamine Commercialization with No Planned Financing, Confirms FDA Approval Goal Date of August 9th, 2025 for Ketamine

July 02, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market

June 24, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Applauds FDA's New Commissioner’s National Priority Voucher (CNPV) Program, Citing Potential to Accelerate its Ketamine Programs for Mental Health, Pain, and Neurological Disorders, and National Security Applications

June 18, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Announces FDA Extends Review Period for Ketamine; New Approval Goal Date August 9, 2025

May 16, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Unveils KetaVault™: A First-of-Its-Kind Portal to Accelerate Ketamine Research and Commercialization

May 14, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Receives US FDA Approval Goal Date for Ketamine

March 11, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher Provides Complete Response Amendment for US FDA New Drug Application for Ketamine

March 03, 2025

Via Newsfile

PharmaTher Provides Update on FDA New Drug Application for Ketamine

February 12, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

PharmaTher CEO Issues Letter to Shareholders

January 06, 2025

From PharmaTher Holdings Ltd.

Via GlobeNewswire

Frequently Asked Questions

Is Pharmather Hldgs Ltd publicly traded?

Yes, Pharmather Hldgs Ltd is publicly traded.

What exchange does Pharmather Hldgs Ltd trade on?

Pharmather Hldgs Ltd trades on the OTC Traded

What is the ticker symbol for Pharmather Hldgs Ltd?

The ticker symbol for Pharmather Hldgs Ltd is PHRRF on the OTC Traded

What is the current price of Pharmather Hldgs Ltd?

The current price of Pharmather Hldgs Ltd is 0.0740

When was Pharmather Hldgs Ltd last traded?

The last trade of Pharmather Hldgs Ltd was at 01/02/26 03:14 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.